Scholarlink

This entry explores the intricate challenges and tailored considerations in pharmacotherapy for individuals with disabilities during the COVID-19 pandemic. Highlighting the disproportionate vulnerabilities faced by this population, it underscores the compounded effects of preexisting health conditions, polypharmacy, and systemic barriers to healthcare access. Pharmacokinetic variations due to altered drug absorption, distribution, metabolism, and excretion are discussed, alongside the complexities introduced by comorbidities such as cardiovascular diseases, diabetes, renal impairment, and respiratory disorders. The role of caregivers emerges as critical, encompassing medication adherence, emotional support, and coordination with healthcare providers. Practical strategies, including simplified medication regimens, adaptive formulations, and leveraging telemedicine, are recommended to enhance accessibility and adherence. Polypharmacy and its associated risks, particularly drug-drug interactions involving COVID-19 therapies like nirmatrelvir/ritonavir, are examined with strategies to mitigate adverse outcomes. This entry also emphasizes the psychological and behavioral dimensions of pharmacotherapy, acknowledging the bidirectional relationship between mental health challenges and COVID-19 treatments. Multidisciplinary care teams, including pharmacists, specialists, and mental health professionals, are advocated for holistic and equitable care delivery. Practical guidelines for clinicians are provided, including individualized treatment plans, dose adjustments for comorbidities, and enhanced monitoring. The need for disability-inclusive research and evidence-based guidelines is highlighted, advocating for systemic changes to address health disparities. By adopting a personalized and multidisciplinary approach, healthcare providers can optimize therapeutic outcomes, ensuring equitable and effective care for disabled populations amidst and beyond the pandemic. This entry serves as a call to action for healthcare systems and researchers to prioritize the unique needs of this vulnerable group.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacotherapy for COVID-19

  • 动态工具书词条

  • 发表日期：

    2025年

查看全文
  • Kaeshaelya Thiruchelvam,
  • Chia Siang Kow,
  • Syed Shahzad Hasan

摘要

This entry explores the intricate challenges and tailored considerations in pharmacotherapy for individuals with disabilities during the COVID-19 pandemic. Highlighting the disproportionate vulnerabilities faced by this population, it underscores the compounded effects of preexisting health conditions, polypharmacy, and systemic barriers to healthcare access. Pharmacokinetic variations due to altered drug absorption, distribution, metabolism, and excretion are discussed, alongside the complexities introduced by comorbidities such as cardiovascular diseases, diabetes, renal impairment, and respiratory disorders. The role of caregivers emerges as critical, encompassing medication adherence, emotional support, and coordination with healthcare providers. Practical strategies, including simplified medication regimens, adaptive formulations, and leveraging telemedicine, are recommended to enhance accessibility and adherence. Polypharmacy and its associated risks, particularly drug-drug interactions involving COVID-19 therapies like nirmatrelvir/ritonavir, are examined with strategies to mitigate adverse outcomes. This entry also emphasizes the psychological and behavioral dimensions of pharmacotherapy, acknowledging the bidirectional relationship between mental health challenges and COVID-19 treatments. Multidisciplinary care teams, including pharmacists, specialists, and mental health professionals, are advocated for holistic and equitable care delivery. Practical guidelines for clinicians are provided, including individualized treatment plans, dose adjustments for comorbidities, and enhanced monitoring. The need for disability-inclusive research and evidence-based guidelines is highlighted, advocating for systemic changes to address health disparities. By adopting a personalized and multidisciplinary approach, healthcare providers can optimize therapeutic outcomes, ensuring equitable and effective care for disabled populations amidst and beyond the pandemic. This entry serves as a call to action for healthcare systems and researchers to prioritize the unique needs of this vulnerable group.